Sionna Therapeutics, Inc. Common Stock (SION) is a publicly traded Healthcare sector company. As of May 20, 2026, SION trades at $39.47 with a market cap of $1.77B and a P/E ratio of -20.62. SION moved +4.78% today. Year to date, SION is -3.30%; over the trailing twelve months it is +181.94%. Its 52-week range spans $7.26 to $48.45. Analyst consensus is strong buy with an average price target of $52.86. Rallies surfaces SION's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Sionna Therapeutics Completes Phase 2a Enrollment, Expects Summer Topline and Holds $289.9M Cash: Sionna Therapeutics completed enrollment in its PreciSION CF Phase 2a proof-of-concept trial for NBD1 stabilizer SION-719 and expects topline data by summer 2026. The company reported a Q1 net loss of $26.8 million, raised R&D spending to $19.0 million, and holds $289.9 million in cash to fund operations through 2028.
| Metric | Value |
|---|---|
| Price | $39.47 |
| Market Cap | $1.77B |
| P/E Ratio | -20.62 |
| EPS | $-1.88 |
| Dividend Yield | 0.00% |
| 52-Week High | $48.45 |
| 52-Week Low | $7.26 |
| Volume | 358.48K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-75.27M |
| Gross Margin | 0.00% |
8 analysts cover SION: 0 strong buy, 7 buy, 0 hold, 1 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $52.86.